Immunic Inc. (NASDAQ:IMUX) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET

Company Participants

Daniel Vitt – Chief Executive officer, President & Director

Glenn Whaley – Vice President of Finance and Principal Financial & Accounting Officer

Conference Call Participants

Thomas Smith – SVB Leerink

Yasmeen Rahimi – Piper Sandler

Andreas Argyrides – Wedbush

Matthew Kaplan – Lautenbach Tallmann

Boobalan Pachaiyappan – H.C. Wainwright

Zegbeh Jallah – Roth Capital

Operator

Good morning and welcome to Immunic's First Quarter 2022 Earnings Call. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's call. Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President as well as Glenn Whaley, our recently promoted Chief Financial Officer. Please note all participants will be in listen-only mode and this event is being recorded. After today's presentation, there will be an opportunity to ask questions. If you joined the webcast via this new platform, there are two ways to submit questions.

You can either submit your question in writing via the Q&A tool of the Zoom portal or if you would like to speak with us directly, please use the raise hand function in the Zoom portal to queue your question. [Operator Instructions] to queue a question. Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate, or words with a similar meaning and such statements involves a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here.

Please note that these forward-looking statements reflect Immunic's opinions only as of the date of this presentation and it undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Please refer to Immunic's SEC filings for a more detailed description of the risk factors that may affect Immunic's results in these forward-looking statements. I would now like to turn the call over to Dr. Daniel Vitt, our CEO and President to begin with the presentation. Daniel, please go ahead.

Daniel Vitt

Thank you, Jessica. I would like to welcome everybody to Immunic's first quarter 2022 earnings call. Earlier this morning, we announced our financial results for the quarter ended March 31st, 2022, and highlighted recent activities as well as upcoming milestones related to our clinical development pipeline. During today's call, we will talk through our first quarter 2022 and subsequent highlights, financial and operating results, as well as anticipated milestones. As Jessica noted, before we close of the call, you will have the opportunity to ask questions. The first quarter of 2022 was marked by continued [Indiscernible]